J&J To Launch Prezista For HIV Immediately Following FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Darunavir - formerly known as TMC-114 - in combination with ritonavir is approved for treatment-experienced adults who do not respond to other antiretrovirals.
You may also be interested in...
Will Continuous Manufacturing Mean Continuous Generic Delay? FDA Hears AAM's Warning
Association for Accessible Medicines calls for US FDA to guard against use of continuous manufacturing methods to protect brand drugs from batch-manufactured generic drugs that may be of lower but still acceptable quality. Then FDA approves first generic of a continuously manufactured drug.
Will Continuous Manufacturing Mean Continuous Generic Delay? FDA Hears AAM's Warning
Association for Accessible Medicines calls for US FDA to guard against use of continuous manufacturing methods to protect brand drugs from batch-manufactured generic drugs that may be of lower but still acceptable quality. Then FDA approves first generic of a continuously manufactured drug.
Prezista Gets New Warning On Hepatotoxicity
FDA issues Medwatch Alert advising health care professionals of updated labeling for Johnson & Johnson’s protease inhibitor.